AKR1C4

Aldo-keto reductase family 1 member C4 · P17516 · AKR1C4 on Sugi Atlas →

28,749 patent compounds predicted against AKR1C4, 19,949 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Indomethacin (SCHEMBL9300)	1.00	2/20
SCHEMBL330545	1.00	2/20
Indomethacin (SCHEMBL42049)	0.98	2/20
Indomethacin (SCHEMBL43583)	0.98	2/20
Indomethacin (SCHEMBL473598)	0.98	2/20
Indomethacin (SCHEMBL41305)	0.96	2/20
Indomethacin (SCHEMBL356273)	0.79	2/20
SCHEMBL453183	0.67	2/20
Indomethacin (SCHEMBL378887)	0.65	2/20
SCHEMBL225014	0.64	2/20
SCHEMBL269614	0.63	2/20
SCHEMBL417027	0.62	2/20
SCHEMBL147187	0.59	2/20
SCHEMBL442397	0.59	2/20
Cinmetacin (SCHEMBL25138)	0.59	2/20
Cinmetacin (SCHEMBL25139)	0.59	2/20
SCHEMBL184715	0.57	2/20
SCHEMBL23567	0.57	2/20
SCHEMBL418984	0.56	2/20
SCHEMBL456875	0.56	2/20

Clinical trials — most relevant to AKR1C4 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
The Role of 5-alpha Reductase in Mediating Testosterone Actions	PHASE4	COMPLETED
Androgen Ablation Therapy With or Without Chemotherapy in Treating Patients With Metastatic Prostate Cancer	PHASE3	COMPLETED
Activity of Regorafenib in Combination With Chemotherapy in Patients With Advanced Biliary Tract Cancer	PHASE1/PHASE2	COMPLETED
Acetylcarnitine and Insulin Sensitivity	PHASE2	COMPLETED
Tolerability of Enteral NAC in Infants	PHASE1	NOT_YET_RECRUITING
Biomarkers in Bone Marrow and Blood Samples From Patients With Prostate Cancer Treated With Ketoconazole	nan	WITHDRAWN
Tissue Predictors of Abiraterone Benefit	nan	COMPLETED
5-Alpha Reductase 2 as a Marker of Resistance to 5ARI Therapy	nan	RECRUITING
Gene Expression, Metabolomic, Microbiome, and Calcium Metabolism in Response to Varied Vitamin D Dosages	nan	COMPLETED
Adrenoleukodystrophy National Registry Study	nan	RECRUITING
Gene Polymorphisms Influencing Steroid Synthesis and Action	nan	WITHDRAWN
Exercise Capacity, Physical Fitness, and Physical Activity Levels in Children With CAH	nan	COMPLETED
Ataxia-telangiectasia: Treating Mitochondrial Dysfunction With Nicotinamide Riboside	nan	UNKNOWN
Pharmacogenetic Determinants Of Treatment Response In Children	nan	RECRUITING
EndoNAFLD: Relationship Between Fatty Liver Disease and Cardiovascular Diseases	nan	COMPLETED
The Clinical and Economic Impact of Pharmacogenomic Testing of Warfarin Therapy in Typical Community Practice Settings	nan	COMPLETED
Final Height in Patients With CAH	nan	UNKNOWN
ALDH2 Genetic Testing in East Asian Community	nan	NOT_YET_RECRUITING
Environmental and Biological Monitoring Pilot Study for Polycyclic Aromatic Hydrocarbons in Linxian, China	nan	COMPLETED
VKORC1 and CYP2C9 Gene Polymorphisms and Warfarin Management	nan	UNKNOWN
Individualized Antiretroviral Therapy	nan	COMPLETED
Influence of WNT4 VEZT FSHB and SIRT1 SNPs in Endometriosis: a Case Control Study of the Sardinian Population	nan	UNKNOWN
A Study of Genetic Influence on LDL Hyper-responsiveness in Patients Following a Ketogenic Diet	nan	RECRUITING
Tamoxifen Pharmacogenetics in Asian Breast Cancer Women	nan	UNKNOWN
Pharmacogenetics of Alcohol: Treatment Implications	nan	COMPLETED
Pattern of Gene Expression in Adipose Tissue From Patients With Cushing Syndrome	nan	COMPLETED
Genetic, Dietary and Environmental Influences on Vitamin D Metabolism	nan	COMPLETED
Aromatase Inhibitor Clinical Trial	nan	UNKNOWN
Gene-by-Smoking Interactions and Risk of Atherosclerosis - Ancillary to ARIC	nan	COMPLETED
Catecholamine Reserve and Exercise Tolerance in Healthy Volunteers and Patients With Congenital Adrenal Hyperplasia	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a AKR1C4 binder may also engage these)

Protein	Name	Similarity
Q1XAA8	—	1.000	Q1XAA8 →
Q95JH5	—	1.000	Q95JH5 →
Q6W8P9	—	1.000	Q6W8P9 →
AKR1C3	Aldo-keto reductase family 1 member C3	0.998	landscape →
Q5R7C9	—	0.997	Q5R7C9 →
Q95JH4	—	0.997	Q95JH4 →
P05980	—	0.997	P05980 →
AKR1C2	Aldo-keto reductase family 1 member C2	0.993	landscape →
P52898	—	0.993	P52898 →
AKR1C1	Aldo-keto reductase family 1 member C1	0.992	landscape →
Q5REQ0	—	0.991	Q5REQ0 →
P80508	—	0.991	P80508 →
P52897	—	0.990	P52897 →
P70694	—	0.986	P70694 →
Q91WR5	—	0.985	Q91WR5 →
Q95JH6	—	0.984	Q95JH6 →
D3ZF77	—	0.984	D3ZF77 →
Q95JH7	—	0.981	Q95JH7 →
Q5T2L2	—	0.976	Q5T2L2 →
Q6AYQ2	—	0.973	Q6AYQ2 →
Q8K023	—	0.967	Q8K023 →
P51652	—	0.966	P51652 →
P23457	—	0.960	P23457 →
Q8VC28	—	0.955	Q8VC28 →
P97382	—	0.953	P97382 →
Q9I8S4	—	0.942	Q9I8S4 →
Q9PTM4	—	0.942	Q9PTM4 →
Q28960	—	0.938	Q28960 →
B2GV72	—	0.936	B2GV72 →
P27119	—	0.936	P27119 →